Pharmaceuticals – Non-Clinical

Expert support for preclinical development

Tailored solutions for toxicology studies and safety assessments.

CRONET supports pharmaceutical and biotech companies through all non-clinical phases of drug development, from early discovery to selection of the best drug candidate. CRONET offers targeted services for the safety evaluation and risk characterization of investigational compounds. Our services are ideal for R&D, preclinical, and regulatory teams seeking a reliable and scientifically solid partner.

Customized De-Risking Strategies

In the early discovery phase, we help clients design and implement tailored toxicology strategies, integrating in-silico (QSAR), in vitro, GLP and non-GLP in vivo approaches. This enables early identification and mitigation of key development risks.

Comprehensive Toxicology Services

Following a thorough gap analysis, our experts provide tailored support in the design and execution of toxicity and safety pharmacology studies; this service includes, for example, protocol definition, laboratory selection, on-site monitoring, and report review for both regulated and non-regulated studies.

Targeted Safety Evaluations

CRONET provides specialized expertise in the early phases of drug development, guiding the design of tailored non-clinical strategies. Through well-planned pharmacodynamics, pharmacokinetics, and early toxicology studies, we help our clients to build a strong foundation for future success.

We also offer risk assessment support for the qualification of impurities in both the active pharmaceutical ingredient (API) and the final drug product. Using advanced tools such as QSAR modeling, read-across justification, and analogue identification we provide solutions for poor data substances in accordance with ICH M7 and ECHA guidelines.

Non-Clinical Pharmacology Studies and Services

CRONET can offer several pharmacological models to assess the efficacy and safety of small molecules and biologics. These non-regulatory studies play a pivotal role in selecting the most promising drug candidates, supporting data-driven decision-making, and streamlining the transition to clinical development.

Client Benefits:

Early risk reduction through strategic toxicology planning
Scientifically sound, regulation-compliant study designs
Efficient lab selection and project coordination
Independent and expert review of study reports
Skilled support for regulatory submissions and discussions